Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (GERN) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class therapies for cancer. The company's cornerstone product candidate is Imetelstat, a novel telomerase inhibitor currently in clinical development. Telomerase is an enzyme that allows cancer cells to maintain telomere length, essential for limitless cellular replication.
Imetelstat is a potent, specific inhibitor of telomerase and holds promise for treating various hematologic myeloid malignancies. Based on clinical data obtained in late 2012, Geron is exploring the potential of Imetelstat to treat conditions such as myelofibrosis (MF), myelodysplastic syndromes (MDS), and acute myelogenous leukemia (AML).
Geron earns revenue through a mix of collaboration agreements, milestones, royalties, and licensing arrangements. The company is the exclusive developer of Imetelstat and possesses various rights to the drug. Operating as a single segment focused on oncology, Geron is committed to advancing its research to bring effective cancer treatments to market.
Stay updated with the latest news and developments from Geron Corporation to learn more about their groundbreaking research and progress in cancer treatment.
Rhea-AI Summary
Geron Corporation (Nasdaq: GERN) Grants Stock Options to Newly Hired Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.35%
Tags
-
Rhea-AI Summary
Geron Corporation (GERN) to Present at Investor Conferences, Webcasts Available - GERN Stock News
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
-
Rhea-AI Summary
Geron Corporation announces publication of abstracts from the IMerge Phase 3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS). The abstracts highlight that imetelstat achieved transfusion independence (TI) in patients across different risk groups and mutational profiles. Nearly 20% of imetelstat-treated patients achieved sustained TI for over 1 year with a median duration of TI of more than 2 years and a median hemoglobin increase of more than 5 g/dL. Imetelstat demonstrated efficacy in patients reclassified as higher risk using molecular international prognostic scoring system (IPSS-M).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
Rhea-AI Summary
Geron Corporation reported business highlights and financial results for Q3 2023. Imetelstat, a telomerase inhibitor, is under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS. The FDA assigned a PDUFA action date of June 16, 2024. Planning is ongoing for a potential commercial launch in the U.S. in mid-2024. Geron has approximately $382 million on the balance sheet as of the end of the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
-
Rhea-AI Summary
Geron Corporation will release its Q3 2023 financial results and business highlights on November 2, 2023. A conference call will be held at 9:00 a.m. ET the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
-
Rhea-AI Summary
Geron Corporation grants stock options to newly hired employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
Rhea-AI Summary
Geron Corporation's Marketing Authorization Application (MAA) for imetelstat has been validated by the European Medicines Agency (EMA), bringing them closer to potentially offering the treatment to lower risk MDS patients in the EU. Clinical results have shown significant efficacy, with higher transfusion independence rates and increased hemoglobin levels in imetelstat-treated patients compared to placebo. The MAA is now under regulatory review and expected to take approximately 14 months. The company is also awaiting a decision from the U.S. FDA with a PDUFA action date of June 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
-
Rhea-AI Summary
Geron Corporation appoints Michelle Robertson as CFO and Treasurer, effective September 25, 2023. Olivia Bloom retires after 30 years with the company. Robertson brings over 30 years of financial experience. Inducement grants of 1.6 million shares of Geron common stock planned for Robertson.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
-
Rhea-AI Summary
Geron announces positive data from IMerge Phase 3 trial for imetelstat in lower risk MDS, with significant increases in transfusion independence and hemoglobin levels, improvement in fatigue, and manageable safety profile. New Drug Application for imetelstat accepted for review by FDA with PDUFA action date of June 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Geron CEO to participate in fireside chat at Baird 2023 Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
FAQ
What is the current stock price of Geron (GERN)?
The current stock price of Geron (GERN) is $3.02 as of January 23, 2025.
What is the market cap of Geron (GERN)?
The market cap of Geron (GERN) is approximately 1.8B.
What is the primary focus of Geron Corporation?
Geron Corporation is focused on developing first-in-class cancer therapies, particularly a telomerase inhibitor named Imetelstat.
What is Imetelstat?
Imetelstat is a novel, first-in-class telomerase inhibitor developed by Geron Corporation for treating various hematologic myeloid malignancies.
Which conditions is Imetelstat being developed to treat?
Imetelstat is being developed to treat myelofibrosis (MF), myelodysplastic syndromes (MDS), and acute myelogenous leukemia (AML).
How does Imetelstat work?
Imetelstat works by inhibiting telomerase, an enzyme that enables cancer cells to maintain telomere length and replicate indefinitely.
What revenue streams does Geron Corporation rely on?
Geron earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements.
Is Geron Corporation a diversified company?
No, Geron operates as a single segment focused on the development of therapeutic products for oncology.
What is the significance of telomerase in cancer treatment?
Telomerase allows cancer cells to maintain telomere length, which is crucial for their endless replication. Inhibiting telomerase can potentially limit cancer growth.
Has Geron Corporation achieved any significant milestones?
Yes, Geron has obtained promising clinical data for Imetelstat and continues to develop it for various cancer treatments.
Where can I find the latest news about Geron Corporation?
You can find the latest news and developments about Geron Corporation on their official website and dedicated stock market websites like StockTitan.
What makes Imetelstat unique among cancer therapies?
Imetelstat is unique because it is a first-in-class telomerase inhibitor, targeting a critical enzyme that allows cancer cells to replicate indefinitely.
Geron Corp
Nasdaq:GERN
GERN Rankings
GERN Stock Data
1.77B
603.98M
0.09%
85.38%
10.67%
Biotechnology
Pharmaceutical Preparations
United States of America
FOSTER CITY